Poly(isobutyl methacrylate) (PIBMA) is a synthetic polymer derived from the monomer isobutyl methacrylate. It is typically synthesized via free-radical polymerization, a process involving the initiation, propagation, and termination of growing polymer chains. PIBMA is known for its good optical clarity, flexibility, and resistance to chemicals, making it a valuable material in various applications. Its biocompatibility and biodegradability have led to its use in biomedical fields, such as drug delivery systems and tissue engineering scaffolds. PIBMA is also employed in coatings, adhesives, and sealants due to its excellent adhesion and water resistance. Researchers study PIBMA to explore its potential in developing new biomaterials, improving existing applications, and understanding the structure-property relationships of polymers. The study of PIBMA's synthesis, degradation, and interactions with biological systems is crucial for advancing its use in various fields.'
| ID Source | ID |
|---|---|
| PubMed CID | 7352 |
| CHEMBL ID | 1453087 |
| SCHEMBL ID | 24562 |
| MeSH ID | M0053280 |
| Synonym |
|---|
| MLS002152907 |
| smr001224512 |
| 2-propenoic acid, 2-methyl-, 2-methylpropyl ester |
| isobutyl 2-methylacrylate |
| inchi=1/c8h14o2/c1-6(2)5-10-8(9)7(3)4/h6h,3,5h2,1-2,4h |
| 97-86-9 |
| nsc18607 |
| isobutyl .alpha.-methacrylate |
| isobutyl methacrylate |
| isobutyl 2-methyl-2-propenoate |
| isobutyl .alpha.-methylacrylate |
| wln: 1y1 & 1ovy1 & u1 |
| nsc-18607 |
| 2-methylpropyl methacrylate |
| methacrylic acid, isobutyl ester |
| NCGC00091087-01 |
| einecs 202-613-0 |
| hsdb 5312 |
| brn 1747595 |
| un2283 |
| isobutylester kyseliny methakrylove [czech] |
| isobutyl alpha-methylacrylate |
| propenoic acid, 2-methyl, isobutyl ester |
| 2-methylpropyl 2-methyl-2-propenoate |
| isobutyl alpha-methacrylate |
| nsc 18607 |
| ccris 4829 |
| isobutyl methacrylate, 97% |
| 9011-15-8 |
| M0132 |
| methacrylic acid isobutyl ester |
| STK801852 |
| 2-methylpropyl 2-methylprop-2-enoate |
| AKOS005622614 |
| NCGC00091087-02 |
| HMS3039B08 |
| tox21_303327 |
| NCGC00256982-01 |
| dtxsid3025461 , |
| dtxcid505461 |
| cas-97-86-9 |
| NCGC00259117-01 |
| tox21_201568 |
| BBL010919 |
| FT-0688079 |
| v11534uyz0 , |
| isobutylester kyseliny methakrylove |
| isobutyl methacrylate, inhibited [un2283] [flammable liquid] |
| ec 202-613-0 |
| unii-v11534uyz0 |
| isobutyl methacrylate, inhibited |
| SCHEMBL24562 |
| isobutyl methacrylate [hsdb] |
| isobutyl methacrylate [inci] |
| isobutyl 2-methylacrylate # |
| blemmer ibma |
| un 2283 |
| i-butyl methacrylate |
| isobutylmethacrylate |
| iso-butyl methacrylate |
| mfcd00084435 |
| CHEMBL1453087 |
| mfcd00008931 |
| isobutyl methacrylate, (stabilized with hq) |
| isobutyl methacrylate (stabilized with hq) |
| VS-02749 |
| Q27291392 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.9587 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 49.6140 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1347035 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 49.6140 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1347035 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.8619 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 2.4659 | 0.0002 | 21.2231 | 8,912.5098 | AID1259247 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 55.2037 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 7.9433 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 3.6895 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 17.1142 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 4.1745 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 3.3969 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 17.4570 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 24.1791 | 0.0002 | 29.3054 | 16,493.5996 | AID1259248; AID743075 |
| caspase-3 | Homo sapiens (human) | Potency | 55.2037 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 5.1155 | 0.0391 | 47.5451 | 146.8240 | AID1224896 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 100.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 23.7101 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| geminin | Homo sapiens (human) | Potency | 32.6427 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||